<DOC>
	<DOCNO>NCT00839059</DOCNO>
	<brief_summary>This Phase I , open-label , multi-center , dose-escalation study lenalidomide adult patient newly diagnose , relapse refractory acute myeloid leukemia . All patient receive lenalidomide per oral daily ( start dose 25 mg/d ) . Cohorts 3 patient ( expand 6 1 dose-limiting toxicity ( DLT ) observe among first 3 patient ) sequentially allot progressively higher dose level lenalidomide basis presence severity lenalidomide-related toxicity lenalidomide relate serious adverse reaction encounter first cycle . For purpose study , patient ' enrollment continue maximum tolerate dose ( MTD ) determine characterize .</brief_summary>
	<brief_title>Lenalidomide In Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Disease state : Age &gt; 70 year newly diagnose AML ( include de novo , sAML , tAML ) consider ineligible intensive treatment . Ineligibility intensive treatment document within case report form ( Medical/Oncologic History ) . Age &gt; 60 year relapsed/refractory AML medically fit patient newly diagnose AML ( include de novo , AML , tAML ) medically unfit patient Age 1860 year : second high relapse AML , eligible intensive therapy WBC &lt; 20x109/l , pretreatment hydroxyurea allow low WBC Prior chemoimmunotherapy studymedications must complete 2 week study treatment start . Treatment hydroxyureas discontinue 1 day initiate dose lenalidomide Willingness ability comply schedule visit , treatment plan , laboratory test study procedure Females childbearing potential ( FCBP ) â€  must agree use two reliable form contraception simultaneously practice complete abstinence FCBP must two negative pregnancy test ( sensitivity least 50 mIU/mL ) prior start study drug . Male subject must agree use latex condom sexual contact female childbearing potential participate study least 28 day follow discontinuation study even undergone successful vasectomy . Acute promyelocytic leukemia [ ( 15 ; 17 ) ] bleed disorder independent AML uncontrolled infection insufficiency kidney ( creatinin &gt; 1.5x upper normal serum level ) , liver ( bilirubin , AST AP &gt; 2x upper normal serum level ) severe obstructive restrictive ventilation disorder heart failure NYHA III/IV severe neurological psychiatric disorder interfere ability give informed consent consent registration , storage process individual diseasecharacteristics course peripheral neuropathy Performance status WHO &gt; 2 Presence medical/psychiatric condition laboratory abnormality may limit full compliance study , increase risk associate study participation study drug administration , may interfere interpretation study result , judgment Investigator , would make patient inappropriate entry study Pregnancy breastfeed Known positive HIV infectious hepatitis , type A , B C Known hypersensitivity thalidomide Any prior use lenalidomide Drug alcohol abuse within last 6 month Participating study within last 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>AML</keyword>
	<keyword>lenalidomide</keyword>
</DOC>